Skip to main content
OpenTrials

Clinical trial condition

Adnexal Diseases

Explore clinical trials studying Adnexal Diseases. Study availability and eligibility vary by location and protocol.

3,504 public trials 677 recruiting studies
Refine in advanced search Browse all conditions

Adnexal Diseases trial results

Active, Not Recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004

Conditions
Adnexal Diseases, Breast, Breast Diseases, +34 more
Locations
  • Research Site Newnan, Georgia, United States
  • Research Site Towson, Maryland, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site Detroit, Michigan, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +21 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587

Conditions
Adnexal Diseases, Advanced or Metastatic Solid Tumors, Breast Cancer, +44 more
Locations
  • HonorHealth Research Institute Phoenix, Arizona, United States
  • The Angeles Clinic Los Angeles, California, United States
  • Hoag Memorial Hospital Newport Beach, California, United States
  • California Pacific Medical Center San Francisco, California, United States
View all 27 locations
View Trial Details
Active, Not Recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

NCT01081262

Conditions
Adnexal Diseases, Borderline Ovarian Mucinous Tumor, Endocrine Gland Neoplasms, +38 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 248 locations
View Trial Details
Active, Not Recruiting

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Arizona Center for Cancer Care (ACCC) - Biltmore Scottsdale, Arizona, United States
  • University of Arizona Cancer Center - Research and Administration at Main Campus Tucson, Arizona, United States
  • Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center Burbank, California, United States
View all 177 locations
View Trial Details

Related conditions